Autobio Diagnostics Co., Ltd. (603658.SS) Bundle
A Brief History of Autobio Diagnostics Co., Ltd.
Founded in 1996, Autobio Diagnostics Co., Ltd. has established itself as a prominent player in the field of in vitro diagnostics (IVD) in China. The company specializes in the research, development, manufacturing, and marketing of diagnostic reagents and equipment.
In 2006, Autobio Diagnostics was listed on the Shenzhen Stock Exchange under the ticker symbol 003006. As of the end of 2022, the company reported a market capitalization of approximately ¥29.5 billion (around $4.3 billion).
Over the years, Autobio has expanded its product range significantly. As of 2023, it offers over 200 products covering various fields such as clinical biochemistry, immunology, microbiology, and molecular diagnostics. In 2022, the company generated revenues of approximately ¥4.2 billion (around $600 million), marking a year-on-year growth rate of 15%.
Autobio's commitment to innovation is evident through its investment in research and development (R&D). Between 2019 and 2022, the R&D expenditure increased from ¥250 million to ¥450 million, accounting for about 10% of its total revenues.
The company has achieved numerous certifications for its products, including ISO 13485 and CE marking, which are essential for commercializing medical devices in Europe and other international markets. In 2021, Autobio received approval for its COVID-19 testing kits, significantly boosting its sales and global presence during the pandemic.
As of October 2023, Autobio Diagnostics has a workforce of over 3,000 employees, with a significant portion engaged in R&D and quality control.
| Year | Revenue (¥ Billion) | Net Income (¥ Billion) | R&D Expenditure (¥ Million) | Market Capitalization (¥ Billion) |
|---|---|---|---|---|
| 2019 | 3.0 | 0.5 | 250 | 15.8 |
| 2020 | 3.4 | 0.6 | 300 | 20.0 |
| 2021 | 3.8 | 0.7 | 400 | 25.0 |
| 2022 | 4.2 | 0.8 | 450 | 29.5 |
In recent years, Autobio has also pursued international markets, establishing partnerships and distribution channels in over 50 countries. The company's strategic expansion into Southeast Asia and Africa in 2022 has further solidified its global footprint.
Looking ahead, Autobio Diagnostics aims to maintain its trajectory of growth by enhancing its product portfolio and increasing R&D efforts. The company's management has set ambitious goals to achieve a revenue target of ¥7 billion by 2025, focusing heavily on innovative diagnostics solutions.
A Who Owns Autobio Diagnostics Co., Ltd.
Autobio Diagnostics Co., Ltd., founded in 2003, is a prominent player in the diagnostics field, particularly in the manufacture of IVD (in-vitro diagnostic) products. The company is publicly traded on the Shenzhen Stock Exchange under the ticker symbol 300459. As of September 2023, Autobio Diagnostics reported a market capitalization of approximately ¥23.14 billion (about $3.5 billion).
The ownership structure of Autobio Diagnostics is characterized by a mix of institutional and individual shareholders, with a significant portion held by the founding members and executive management. According to the latest filings, key shareholders include:
| Shareholder | Ownership Percentage | Shares Owned (in millions) |
|---|---|---|
| Beijing Chunlian Investment Co., Ltd. | 29.68% | 80.25 |
| Feng Hongliang (CEO) | 10.25% | 27.75 |
| Guangdong No. 1 Investment Co., Ltd. | 6.58% | 17.50 |
| Public Float | 53.49% | 142.50 |
In 2022, Autobio Diagnostics reported total revenues of ¥4.16 billion (approximately $642 million), representing a year-over-year growth of 18%. The company’s net profit for the same period was approximately ¥640 million (around $99 million), translating to a net profit margin of 15.4%.
Furthermore, Autobio Diagnostics has made significant investments in R&D, allocating about ¥550 million (approximately $84 million) in 2022, which accounted for about 13.2% of its total revenue. This focus on innovation is evident in the numerous patents filed for new diagnostic technologies.
Internationally, Autobio Diagnostics has expanded its footprint, exporting products to over 50 countries. The company’s strategic partnerships with various healthcare organizations and distributors have bolstered its global presence, further driving revenue growth.
The long-term prospects of Autobio Diagnostics appear promising as the demand for diagnostic products continues to rise, especially in the wake of global health initiatives. Its current stock performance reflects a yearly growth of approximately 35% year to date, indicating strong investor confidence and market positioning.
Autobio Diagnostics Co., Ltd. Mission Statement
Autobio Diagnostics Co., Ltd. specializes in the production of in vitro diagnostics (IVD) products. The company's mission is to innovate and provide high-quality diagnostic solutions that enhance healthcare outcomes globally. With a strong commitment to research and development, Autobio aims to improve the efficiency and accuracy of disease detection.
As of 2022, Autobio recorded significant financial milestones, emphasizing its growth trajectory in the diagnostics market. The company reported an annual revenue of RMB 1.75 billion, reflecting a year-on-year growth of 13.5%.
The company's market capitalization as of October 2023 stands at approximately RMB 25 billion, indicating a robust investor confidence in its operational strategies and product lines. Autobio has successfully expanded its product portfolio, now featuring over 100 different IVD products that cater to various medical fields, including immunology, respiratory diseases, and infectious diseases.
Central to Autobio's mission is its focus on research and development, with around 10% of its revenue reinvested into R&D initiatives. The company employs over 1,500 professionals across its R&D and manufacturing facilities, contributing to groundbreaking advancements in diagnostic technologies.
| Key Financial Metrics | 2021 | 2022 | 2023 (Est.) |
|---|---|---|---|
| Annual Revenue (RMB) | RMB 1.54 billion | RMB 1.75 billion | RMB 1.90 billion |
| Net Profit (RMB) | RMB 250 million | RMB 290 million | RMB 320 million |
| Market Capitalization (RMB) | RMB 20 billion | RMB 25 billion | RMB 30 billion |
| R&D Investment (% of Revenue) | 9% | 10% | 10% |
As part of its mission, Autobio is dedicated to expanding its global footprint, with exports accounting for approximately 30% of total revenue in 2022. The company is actively pursuing partnerships and collaborations both domestically and internationally to align with its goal of improving global health standards through superior diagnostic products.
Autobio's commitment to quality is reflected in its certifications. The company has received ISO 13485 and CE marking for many of its products, showcasing compliance with international standards for quality management systems specific to the medical devices sector.
Furthermore, Autobio continues to adapt to changing market dynamics, increasingly focusing on point-of-care testing solutions to address the rising demand for rapid diagnostics driven by health crises such as pandemics.
The company’s strategic initiatives and performance metrics underscore its dedication to the mission of delivering cutting-edge diagnostic solutions to improve patient care worldwide.
How Autobio Diagnostics Co., Ltd. Works
Autobio Diagnostics Co., Ltd. is a prominent player in the in-vitro diagnostic industry, specializing in rapid diagnostic testing solutions. Founded in 2001 and headquartered in Hefei, China, the company develops a wide array of diagnostic instruments and reagents for various diseases, including infectious diseases, diabetes, and tumors.
In 2022, Autobio Diagnostics reported total revenues of approximately RMB 1.28 billion, representing a year-over-year growth of 22%. The company's profitability is reflected in its net profit of around RMB 310 million, marking an increase of 15% from the previous year.
Business Segments
Autobio operates in several business segments:
- Reagents
- Diagnostic Instruments
- Services
The revenue distribution for 2022 was as follows:
| Segment | Revenue (RMB million) | Percentage of Total Revenue |
|---|---|---|
| Reagents | 800 | 62.5% |
| Diagnostic Instruments | 400 | 31.25% |
| Services | 80 | 6.25% |
Product Lines
Autobio offers a broad range of products, including:
- Microbiology and immunology tests
- Clinical chemistry tests
- Point-of-care testing devices
- Self-testing products
In 2023, the company launched a new line of SARS-CoV-2 rapid antigen tests, which contributed to a significant portion of their current sales, accounting for approximately 15% of total revenues in the first quarter.
Market Presence
Autobio Diagnostics has a strong market presence both domestically and internationally. As of 2022, the company exported products to over 30 countries, including the US, Germany, and Brazil. The international sales contributed roughly 25% of total revenue, while domestic sales accounted for approximately 75%.
Research and Development
In an effort to maintain its competitive edge, Autobio invested about RMB 100 million in R&D in 2022, representing roughly 7.8% of total revenue. This investment has led to advancements in diagnostic technology and new product development.
Financial Performance Metrics
| Metric | 2021 | 2022 | 2023 (Q1) |
|---|---|---|---|
| Total Revenue (RMB million) | 1,050 | 1,280 | 350 |
| Net Profit (RMB million) | 270 | 310 | 90 |
| Gross Margin (%) | 45% | 46% | 47% |
Company shares are traded on the Shenzhen Stock Exchange under the ticker symbol 300849.SZ. As of October 2023, the stock price stands at approximately RMB 45 per share, with a market capitalization of around RMB 15 billion.
Autobio's growth strategy focuses on expanding its product portfolio and enhancing its distribution capabilities. The company's commitment to quality and innovation positions it well for future growth in the booming healthcare sector.
How Autobio Diagnostics Co., Ltd. Makes Money
Autobio Diagnostics Co., Ltd. primarily generates revenue through the development, manufacturing, and sale of in vitro diagnostic products. This includes a wide range of diagnostic kits, instruments, and reagents used in clinical laboratories and hospitals.
Product Categories
The company’s revenue streams can be categorized into several key product lines:
- Diagnostic Reagents: These are kits used for various tests including serological, immunological, and molecular diagnosing. In 2022, this segment contributed approximately 60% of total revenue.
- Testing Instruments: Autobio produces instruments that automate diagnostic processes, increasing efficiency in labs. This category accounted for around 25% of their revenue in the last fiscal year.
- After-sales Services: Offering maintenance and support for their products, this service line generates about 15% of their total revenue.
Geographical Revenue Distribution
Autobio Diagnostics has a significant presence in various markets, with revenue generated primarily in:
- China: Approximately 70% of the company’s revenue comes from the domestic market.
- International Markets: The remaining 30% is sourced from international sales, including regions such as Europe and the Americas.
Financial Performance Overview
For the fiscal year ending December 2022, Autobio Diagnostics reported total revenues of approximately ¥1.5 billion (around $230 million USD). The breakdown of revenues is as follows:
| Product Category | Revenue (¥) | Percentage of Total Revenue |
|---|---|---|
| Diagnostic Reagents | ¥900 million | 60% |
| Testing Instruments | ¥375 million | 25% |
| After-sales Services | ¥225 million | 15% |
Market Trends and Growth
The in vitro diagnostics market is projected to grow at a compound annual growth rate (CAGR) of around 7% from 2023 to 2030. Autobio is well-positioned to capitalize on this growth due to:
- Strong R&D capabilities with a focus on innovative diagnostic solutions.
- Partnerships with hospitals and healthcare providers to enhance product visibility and access.
- Adaptation to global trends towards personalized medicine which drives demand for more specialized diagnostics.
Recent Developments
In 2023, Autobio Diagnostics launched several new products, including a rapid COVID-19 test kit, which has gained popularity in both domestic and international markets. This expansion is expected to contribute an additional ¥200 million in revenue for the current fiscal year.
Additionally, the company's strategic move to enhance its online sales platform has seen a 30% increase in direct-to-consumer sales, facilitating better access to their diagnostic products.
Conclusion
Autobio Diagnostics Co., Ltd. continues to leverage its strong product portfolio and market positioning to drive revenue across its various business segments.
Autobio Diagnostics Co., Ltd. (603658.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.